Associations between an obesity related genetic variant (FTO rs9939609) and prostate cancer risk

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Lewis, Sarah J ^a   Murad, Ali ^a   Chen, Lina ^a   Smith, George Davey ^a   Donovan, Jenny ^a   Palmer, Tom ^a   Hamdy, Freddie ^b   Neal, David ^c   Lane, J Athene ^a   Davis, Michael ^a   Cox, Angela ^d   Martin, Richard M ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; BODY MASS; CANCER GRADING; CANCER RISK; CONTROLLED STUDY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PHENOTYPE; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; GENETICS; GENOTYPE; MIDDLE AGED; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

AGED; BODY MASS INDEX; CASE-CONTROL STUDIES; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; OBESITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 78149419139     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013485     Document Type: Article

References (44)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global Cancer Statistics, 2002. CA Cancer J Clin 55: 74-108.
2. Crawford ED (2003) Epidemiology of prostate cancer. Urology 62(6, Supplement 1): 3-12.
3. World Cancer Research Fund/American Institute for Cancer Research, Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. Washington DC: AICR, 2007.
4. Macinnis RJ, English DR (2006) Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 17: 989-1003.
5. Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, et al. (2006) Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 15: 1977-1983.
6. Rodriguez C, Freedland SJ, Deka A, et al. (2007) Body Mass Index, Weight Change, and Risk of Prostate Cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 16: 63-69.
7. Wright ME, Chang SC, Schatzkin A, et al. (2007) Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 109: 675-684.
8. Buschemeyer III WC, Freedland SJ (2007) Obesity and Prostate Cancer: Epidemiology and Clinical Implications. European Urology 52: 331-343.
9. Freedland SJ, Giovannucci E, Platz EA (2006) Are Findings from Studies of Obesity and Prostate Cancer Really in Conflict? Cancer Causes and Control 17: 5-9.
10. Turner EL, Lane JA, Donovan JL, Davis MJ, Metcalfe C, et al. (2010) Association of diabetes mellitus with prostate cancer: Nested case-control study (protect: Prostate testing for cancer and treatment). Int J Cancer. Apr 5: [Epub ahead of print] DOI: 10.1002/ijc.25360.
11. Kasper JS, Giovannucci E (2006) A Meta-analysis of Diabetes Mellitus and the Risk of Prostate Cancer. Cancer Epidemiol Biomarkers Prev 15: 2056-2062.
12. Baillargeon J, Pollock BH, Kristal AR, et al. (2005) The association of body mass index and prostate-specific antigen in a population-based study. Cancer 103: 1092-1095.
13. Barqawi AB, Golden BK, OÆDonnell C, Brawer MK, Crawford ED (2005) Observed effect of age and body mass index on total and complexed PSA: Analysis from a national screening program. Urology 65: 708-712.
14. Werny DM, Thompson T, Saraiya M, et al. (2007) Obesity Is Negatively Associated with Prostate-Specific Antigen in US Men, 2001-2004. Cancer Epidemiology Biomarkers & Prevention 16: 70-76.
15. Banez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, et al. (2007) Obesityrelated plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 98: 2275-2280.
16. Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR (2007) Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer 109: 1192-1202.
17. Freedland SJ, Aronson WJ, Kane CJ, et al. (2004) Impact of Obesity on Biochemical Control After Radical Prostatectomy for Clinically Localized Prostate Cancer: A Report by the Shared Equal Access Regional Cancer Hospital Database Study Group. J Clin Oncol 22: 446-453.
18. Millender LE, Aubin M, Pouliot J, Shinohara K, Roach M (2004) Daily electronic portal imaging for morbidly obese men undergoing radiotherapy for localized prostate cancer. International Journal of Radiation Oncology*Biology* Physics 59: 6-10.
19. van Roermund J, Witjes J (2007) The impact of obesity on prostate cancer. World Journal of Urology 25: 491-497.
20. Hsing AW, Chu LW, Stanczyk FZ (2008) Androgen and Prostate Cancer: Is the Hypothesis Dead? Cancer Epidemiol Biomarkers Prev 17: 2525-2530.
21. Davey Smith G, Ebrahim S (2003) 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 32: 1-22.
22. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G (2008) Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology. Stat Med 27: 1133-1163.
23. Frayling TM, Timpson NJ, Weedon MN, et al. (2007) A Common Variant in the FTO Gene Is Associated with Body Mass Index and Predisposes to Childhood and Adult Obesity. Science 316: 889-894.
24. Peeters A, Beckers S, Verrijken A, et al. (2008) Variants in the FTO gene are associated with common obesity in the Belgian population. Molecular Genetics and Metabolism 93: 481-484.
25. Scuteri A, Sanna S, Chen W, Uda M, Albai G (2007) Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related. PLoS Genet 3: e115.
26. Hotta K, Nakata Y, Matsuo T, et al. (2008) Variations in the FTO gene are associated with severe obesity in the Japanese. Journal of Human Genetics 53: 546-553.
27. Wardle J, Carnell S, Haworth CMA, et al. (2008) Obesity Associated Genetic Variation in FTO Is Associated with Diminished Satiety. J Clin Endocrinol Metab 93: 3640-3643.
28. Timpson NJ, Emmett PM, Frayling TM, et al. (2008) The fat mass- and obesityassociated locus and dietary intake in children. American Journal of Clinical Nutrition 2008; 88: 971-978.
29. Wittekind C, Compton C, Greene FE, Sobin LH (2002) TNM residual tumor classification revisited. Cancer 94: 2511-2516. 33: 42-45.
30. Avery KNL, Blazeby JM, Lane JA, et al. (2008) Decision-Making about PSA Testing and Prostate Biopsies: A Qualitative Study Embedded in a Primary Care Randomised Trial. European Urology 53: 1186-1193.
31. Donovan J, Hamdy F, Neal D, et al. (2003) Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess 7: 1-88.
32. Zuccolo L, Harris R, Gunnell D, et al. (2008) Height and Prostate Cancer Risk: A Large Nested Case-Control Study (ProtecT) and Meta-analysis. Cancer Epidemiology Biomarkers & Prevention 17: 2325-2336.
33. Didelez V, Sheehan N (2007) Mendelian randomization as an instrumental variable approach to causal inference. Statistical Methods in Medical Research 16: 309-330.
34. Minelli C, Thompson JR, Tobin MD, Abrams KR (2004) An integrated approach to the meta-analysis of genetic association studies using Mendelian randomization. American Journal of Epidemiology 160: 8211; 452.
35. Thomas DC, Lawlor DA, Thompson JR (2007) RE: estimation of bias in nongenetic observational studies using ''Mendelian randomization'' by Bautista et al., Annals of Epidemiology 17: 511-513.
36. Chen L, Davey Smith G, Evans DM, Cox A, Lawlor DA (2009) Genetic variants in the vitamin d receptor are associated with advanced prostate cancer at diagnosis: findings from the prostate testing for cancer and treatment study and a systematic review. Cancer Epidemiol Biomarkers Prev 18: 2874-2881.
37. Steuber T, Erbersdobler A, Graefen M (2006) Comparative assessment of the 1992 and 2002 pathologic T3 substages for the prediction of biochemical recurrence after radical prostatectomy. Cancer 106: 775-782.
38. Timpson NJ, Emmett P, Frayling TM, Rogers I, Hattersley AT, et al. (2008) The FTO/obesity associated locus and dietary intake in children. Am J Clin Nutr 88: 971-978.
39. Fischer J, Koch L, Emmerling C, Vierkotten J, Peters T, et al. (2009) Inactivation of the Fto gene protects from obesity. Nature 458: 894-898.
40. Stratigopoulos G, Padilla SL, LeDuc CA, Watson E, Hattersley AT, et al. (2008) Regulation of Fto/Ftm gene expression in mice and humans. Am J Physiol Regul Integr Comp Physiol 294: R1185-R1196.
41. Cecil JE, Tavendale R, Watt P, Hetherington MM, Palmer CAN (2008) An obesity-associated FTO gene variant and increased energy intake in children. N Engl J Med 359: 2558-2566.
42. Gerken T, Girard CA, Tung YL, Webby CJ, Saudek V, et al. (2007) The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase. Science 318: 1469-1472.
43. Davey Smith G. Use of genetic markers and gene-diet interactions for interrogating population-level causal influences of diet on health. Genes Nutr. In press, DOI 10.1007/is12263-010-0181-y.
44. Pierce BL, Ahsan H, VanderWeele TJ. Power and instrument strength requirements for Mendelian randomization using multiple genetic variants. Int J Epidemiol. In press.